Organogenesis Holdings Inc (NASDAQ:ORGO) price on current trading day, rose 10.27% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $4.08.
A look at the stock’s price movement, the close in the last trading session was $3.70, moving within a range at $3.53 and $4.255. The beta value (5-Year monthly) was 1.797 while the PE ratio in trailing twelve months stood at 728.57. Turning to its 52-week performance, $6.71 and $2.16 were the 52-week high and 52-week low respectively. Overall, ORGO moved -23.02% over the past month.
Organogenesis Holdings Inc’s market cap currently stands at around $517.45 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-26.
Analysts have a consensus estimate of 90.77M for the company’s revenue for the quarter, with a low and high estimate of 87.7M and 93.8M respectively. The average forecast suggests down to a -17.47% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 488.25M, representing a 1.29% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ORGO is a 50% Buy. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend ORGO as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ORGO’s current price about -11.42% and -4.99% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 44.13, while 7-day volatility ratio is 12.88% and 7.91% in the 30-day chart. Further, Organogenesis Holdings Inc (ORGO) has a beta value of 1.82, and an average true range (ATR) of 0.41. Analysts have given the company’s stock an average 52-week price target of $6, forecast between a low of $6 and high of $6. Looking at the price targets, the low is -47.06% off current price level while to achieve the yearly target high, price needs to move -47.06%. Nonetheless, investors will most likely welcome a -47.06% jump to $6 which is the analysts’ median price.
If we refocus on Organogenesis Holdings Inc (NASDAQ:ORGO), historical trading data shows that trading volumes averaged 1.2 over the past 10 days and 1.87 million over the past 3 months. The company’s latest data on shares outstanding shows there are 125.73 million shares.
The 49.24% of Organogenesis Holdings Inc’s shares are in the hands of company insiders while institutional holders own 49.45% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 8.62 million on 2025-03-14, giving us a short ratio of 2.12. The data shows that as of 2025-03-14 short interest in Organogenesis Holdings Inc (ORGO) stood at 2878.0 of shares outstanding, with shares short falling to 8.67 million registered in 2025-02-14. Current price change has pushed the stock 27.50% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ORGO stock continues to rise going into the next quarter.
